FGFR2 and cholangiocarcinoma: It is the first targeted treatment approved for cholangiocarcinoma in the United States, the European Union, Japan, and Taiwan (China), indicated for previously treated cholangiocarcinoma with an FGFR2 fusion or rearrangement.22, 23, 24, 25